Who founded Chrysalis Biotherapeutics?

Chrysalis Biotherapeutics was founded by Darrell H. Carney, Laurie Sower.

How much funding has Chrysalis Biotherapeutics raised?

Chrysalis Biotherapeutics has disclosed $515K raised across 1 round.

Where is Chrysalis Biotherapeutics headquartered?

Chrysalis Biotherapeutics is headquartered in Galveston, US.

Chrysalis Biotherapeutics

Galveston, US · Delaware corporation

Find your way into Chrysalis Biotherapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Chrysalis Biotherapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Chrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.

Biotech Healthtech

Founders & leadership

Darrell H. Carney PhDDarrell H. Carney is a biochemist who spent over 30 years as a professor at the University of Texas Medical Branch, conducting research on thrombin receptors and peptide-based tissue regeneration before founding Chrysalis BioTherapeutics in 2012 to develop therapeutics targeting radiation exposure and, more recently, acute respiratory distress syndrome.

Laurie SowerPhD

Jerry BatyJD, CPA, MBA

Lauri SowerNamed on SEC filing

Timothy SchmidtMBA

Marie RobbNamed on SEC filing

Jeffery SheldonMBA

Board

Gerald M FullerPhD

Steven PikulinPhD

James T. RyabyPhD

Reported raises · per SEC filings

Form D private placements

$515K disclosed across 1 round · 2023

▶$515KraisedMar 2024 · 12 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Lauri SowerExecutive Officer
Darrell CarneyExecutive Officer, Director
Timothy SchmidtDirector
James RyabyDirector
Marie RobbDirector
Jeffery SheldonDirector

Offering amount: $3M
Amount sold: $515K
Minimum investment: $10K
Proceeds to insiders: $139K
First sale: Nov 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Krystal BiotechKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.

Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Chrysalis Biotherapeutics.

Frequently asked questions

What does Chrysalis Biotherapeutics do?: Chrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.
Who founded Chrysalis Biotherapeutics?: Chrysalis Biotherapeutics was founded by Darrell H. Carney, Laurie Sower.
How much funding has Chrysalis Biotherapeutics raised?: Chrysalis Biotherapeutics has disclosed $515K raised across 1 round.
Where is Chrysalis Biotherapeutics headquartered?: Chrysalis Biotherapeutics is headquartered in Galveston, US.